These drugs have also been shown to inhibit tumor progression by altering the expression levels of proteins related to cell cycle and apoptosis such as CCNE1, CDK4 and BCL-2, and by inhibiting drug efflux pumps (Spengler et al., 2016; Qian et al., 2019). This evidence concerns the gene BCL2 and neoplasm.